Literature DB >> 26187290

Current practice of first-line treatment strategies in patients with critical limb ischemia.

Theodosios Bisdas1, Matthias Borowski2, Giovanni Torsello3.   

Abstract

OBJECTIVE: Critical limb ischemia (CLI) is growing in global prevalence and is associated with high rates of limb loss and mortality. However, a relevant gap of evidence about the most optimal treatment strategy still exists. The aim of this study of the prospective, multicenter First-Line Treatments in Patients With Critical Limb Ischemia (CRITISCH) registry was to assess the current practice of all first-line treatments strategies in CLI patients in German vascular centers.
METHODS: Between January 2013 and September 2014, five first-line treatment strategies-endovascular revascularization (ER), bypass surgery (BS), femoral/profundal artery patchplasty (FAP), conservative treatment, and primary amputation-were determined among CLI patients in 27 vascular tertiary centers. The main composite end point was major amputation or death, or both, during the hospital stay. Secondary outcomes were hemodynamic failure, major adverse cardiovascular and cerebral events, and reintervention. Univariate logistic models were additionally built to preselect possible risk factors for either event, which were then used as candidates for a multivariate logistic model.
RESULTS: The study included 1200 consecutive patients. First-line treatment of choice was ER in 642 patients (53.4%), BS in 284 (23.7%), FAP in 126 (10.5%), conservative treatment in 118 (9.8%), and primary amputation in 30 (2.5%). The composite end point was met in 24 patients (4%) after ER, in 17 (6%) after BS, in 8 (6%) after FAP, and in 9 (8%) after conservative treatment (P = .172). The highest rate of in-hospital death was observed after primary amputation (10%) and of hemodynamic failure after conservative treatment (91%). Major adverse cardiovascular and cerebral events developed in 4% of patients after ER, in 5% after BS, in 6% after FAP, in 5% after conservative treatment, and in 13% after primary amputation. The reintervention rate was 8%, 14%, 6%, 5%, and 3% in each group, respectively. In the multivariate regression model, coronary artery disease (odds ratio [OR], 2.96; 95% confidence interval [CI], 1.42-6.17) and previous myocardial infarction (PMI) <6 months (OR, 3.67, 95% CI, 1.51-8.88) were identified as risk factors for the composite end point. Risk factors for amputation were dialysis (OR, 3.31, 95% CI, 1.44-7.58) and PMI (OR, 3.26, 95% CI, 1.23-8.36) and for death, BS compared with ER (OR, 3.32; 95% CI, 1.10-10.0), renal insufficiency without dialysis (OR, 6.34; 95% CI, 1.71-23.5), and PMI (OR, 7.41; 95% CI, 2.11-26.0).
CONCLUSIONS: The CRITISCH registry revealed ER as the most common first-line approach in CLI patients. Coronary artery disease and PMI <6 months were independent risk factors for the composite end point. Special attention should be also paid to CLI patients with renal insufficiency, with or without dialysis, and those undergoing BS.
Copyright © 2015 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26187290     DOI: 10.1016/j.jvs.2015.04.441

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  14 in total

Review 1.  Endovascular Treatment of Infrapopliteal Peripheral Artery Disease.

Authors:  Ehrin J Armstrong; Kalkidan Bishu; Stephen W Waldo
Journal:  Curr Cardiol Rep       Date:  2016-04       Impact factor: 2.931

2.  Patient selection and perioperative outcomes of bypass and endovascular intervention as first revascularization strategy for infrainguinal arterial disease.

Authors:  Thomas C F Bodewes; Jeremy D Darling; Sarah E Deery; Thomas F X O'Donnell; Alexander B Pothof; Katie E Shean; Frans L Moll; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2017-08-24       Impact factor: 4.268

Review 3.  [Endovascular versus conventional vascular surgery--old-fashioned thinking? Part 2: carotid artery stenosis and peripheral arterial occlusive disease].

Authors:  E S Debus; D Manzoni; C-A Behrendt; F Heidemann; R T Grundmann
Journal:  Chirurg       Date:  2016-04       Impact factor: 0.955

4.  Long-Term Patency and Clinical Outcomes of Nitinol Stenting for Femoropopliteal Atherosclerotic Disease.

Authors:  Sherwin Abdoli; Steven Katz; Christian Ochoa
Journal:  Ann Vasc Surg       Date:  2019-11-06       Impact factor: 1.607

Review 5.  Therapeutic Alternatives in Diabetic Foot Patients without an Option for Revascularization: A Narrative Review.

Authors:  Gerhard Ruemenapf; Stephan Morbach; Martin Sigl
Journal:  J Clin Med       Date:  2022-04-12       Impact factor: 4.964

6.  Results of peripheral bypass surgery in patients with critical limb ischemia (CRITISCH registry).

Authors:  T Bisdas; G Torsello; A Stachmann; R T Grundmann
Journal:  Gefasschirurgie       Date:  2016-07-13

7.  Recent Progress of Bypass Surgery to the Dialysis-Dependent Patients with Critical Limb Ischemia.

Authors:  Nobuyoshi Azuma; Shinsuke Kikuchi; Hiroko Okuda; Keisuke Miyake; Atsuhiro Koya
Journal:  Ann Vasc Dis       Date:  2017-09-25

8.  Comparison of Clinical Outcomes after Surgical and Endovascular Revascularization in Hemodialysis Patients with Critical Limb Ischemia.

Authors:  Tatsuya Shiraki; Osamu Iida; Mitsuyoshi Takahara; Yoshimitsu Soga; Shinsuke Mii; Jin Okazaki; Sosei Kuma; Terutoshi Yamaoka; Daisuke Kamoi; Yoshiaki Shintani; Toshinobu Ishikawa; Ikuro Kitano; Masaaki Uematsu
Journal:  J Atheroscler Thromb       Date:  2016-10-13       Impact factor: 4.928

9.  Percutaneous endovascular treatment of infrainguinal PAOD: Results of the PSI register study in 74 German vascular centers.

Authors:  C-A Behrendt; F Heidemann; K Haustein; R T Grundmann; E S Debus
Journal:  Gefasschirurgie       Date:  2016-10-28

10.  The endovascular performance spectrum of vascular surgery departments in Germany: Results of an online survey among senior department physicians.

Authors:  T Schmitz-Rixen; G Torsello; M Steinbauer; R T Grundmann
Journal:  Gefasschirurgie       Date:  2016-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.